A spin-out of University of Pennsylvania, Novapeutics LLC is tackling treating diabetes by using menin inhibitors to regenerate insulin producing beta cells. Diabetics do not have enough insulin and/or are less responsive to insulin. Their work suggests that Menin Inhibitors can increase the number of functional beta cells and reduce stress in beta cells, resulting in maximizing insulin output.
